Inhibition of Siderophore Biosynthesis for Tuberculosis Drug Discovery

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/632769

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Tuberculosis (TB) is responsible for over 2 million deaths globally every year. Despite this alarming statistic, no new TB drugs have reached the market in 40 years. This is despite the emergence of strains of Mycobacterium tuberculosis (the causative agent of TB) that are resistant to currently prescribed drugs. This project aims to discover TB drug leads with a unique mode of action. This will be achieved by preparing compounds that prevent the bacterium from acquiring iron from the host.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $424,262.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medicinal and Biomolecular Chemistry not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Mycobacterium tuberculosis | antibacterial drug discovery | antibacterials | drug resistance | enzyme inhibitors | medicinal chemistry | siderophores | structure-based drug design | tuberculosis

Related Links